Morrisette, T.; Alosaimy, S.; Abdul-Mutakabbir, J.C.; Kebriaei, R.; Rybak, M.J.
The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy. Antibiotics 2020, 9, 762.
https://doi.org/10.3390/antibiotics9110762
AMA Style
Morrisette T, Alosaimy S, Abdul-Mutakabbir JC, Kebriaei R, Rybak MJ.
The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy. Antibiotics. 2020; 9(11):762.
https://doi.org/10.3390/antibiotics9110762
Chicago/Turabian Style
Morrisette, Taylor, Sara Alosaimy, Jacinda C. Abdul-Mutakabbir, Razieh Kebriaei, and Michael J. Rybak.
2020. "The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy" Antibiotics 9, no. 11: 762.
https://doi.org/10.3390/antibiotics9110762
APA Style
Morrisette, T., Alosaimy, S., Abdul-Mutakabbir, J. C., Kebriaei, R., & Rybak, M. J.
(2020). The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy. Antibiotics, 9(11), 762.
https://doi.org/10.3390/antibiotics9110762